A CLINICAL ASSESSMENT OF THE QUADRUPLE COMBO INCLUDING EPLERENONE, IVABRADINE, CLOPIDOGREL, ROSUVASTATIN IN 144 HUMAN SUBJECTS WITH OVERT HEART FAILURE
Abstract:
Aim. An assessment of the quadruple combo eplerenone, ivabradine, clopidogrel, rosuvastatin behaviour in heart failure, in terms of clinical pharmacology, in order to use it, eventually, on a large scale in cardiovascular prevention vs. 288 controls. Method. 144 patients with heart failure documented by biomarkers, treated 6 months with the quadruple combo. Results. The combo proved high efficacy in clinical, haemodynamic, imaging, quality-of-life terms and safety. Conclusions. The combo could be used on larger scale in benefit of cardiovascular patients along the cardiovascular continuum.
full text article in Romanian (.RO) |
full text article in English (.EN) |